Clinical trials: Testosterone
Hypogonadism
Open-Label Study of ARD-0403 in Testosterone Deficient Men
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient wellbeing.
- Trial name
- NCT00448955
- Testing
- ARD-0403
- Where
- 12 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ardana Bioscience Ltd
Male Hypogonadism
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
- Trial name
- NCT01403116
- Testing
- Oral testosterone undecanoate, topical testosterone gel
- Where
- 30 sites in United States, Germany
- Volunteers
- 325 people
- Sponsor
- Clarus Therapeutics, Inc.
Hypogonadism, Male
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month…
- Trial name
- NCT03198728
- Testing
- SOV2012-F1, AndroGel
- Where
- 36 sites in United States
- Volunteers
- 314 people
- Sponsor
- Marius Pharmaceuticals
Testicular Hypogonadism
Efficacy, Pharmacokinetics and Safety of Testosterone
This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations < 297 ng/dL.
- Trial name
- NCT01370369
- Testing
- Testosterone gel (FE 99903)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Hypoactive Sexual Desire Disorder
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.
- Trial name
- NCT00384046
- Testing
- Testosterone
- Where
- 31 sites in Australia, Botswana and 3 more
- Volunteers
- 272 people
- Sponsor
- Warner Chilcott
Prostate Cancer
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Some patients with prostate cancer benefit from androgen deprivation therapy which reduces levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone (LHRH) analogue which upon administration can…
- Trial name
- NCT01415960
- Testing
- Leuprolide acetate 22.5 mg depot, GP-Pharm SA
- Where
- 25 sites in United States
- Volunteers
- 163 people
- Sponsor
- GP-Pharm
Male Hypogonadism
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
- Trial name
- SOAR (NCT02081300)
- Testing
- Oral testosterone undecanoate, LPCN 1021, Topical testosterone gel 1.62 %
- Volunteers
- 315 people
- Sponsor
- Lipocine Inc.
Hypogonadism
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
This study will evaluate if testosterone solution can raise testosterone hormone levels into the normal range after treatment for up to 9 Weeks, in those participants with a documented history of subtherapeutic levels [total…
- Trial name
- NCT01893281
- Testing
- Topical Testosterone Solution
- Where
- 21 sites in United States
- Volunteers
- 78 people
- Sponsor
- Eli Lilly and Company
Hypogonadism, Hypogonadism, Male
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
This will be a phase 1/2a, open-label, single-center study with 3 periods. The aims of the study are to: 1. evaluate the dose-response curve following ascending single doses of TSX-011; 2. confirm optimum dosing conditions; 3.
- Conditions
- Hypogonadism, Hypogonadism, Male, Gonadal Disorders, Endocrine System Diseases
- Trial name
- NCT03335254
- Testing
- TSX-011
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- TesoRx Pharma, LLC
Known Androgen Deficiency
Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men
Low testosterone is a common male problem. The diagnosis of low testosterone often requires blood sampling and expensive testing. We want to know if measuring saliva testosterone can be used in place of blood sampling.
- Trial name
- NCT01909505
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Saliva Biomarkers, Inc.
Hypogonadism, Paraplegia
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to decreased bone mineral density resp osteoporosis.
- Conditions
- Hypogonadism, Paraplegia, Bone Density, Osteoporosis
- Trial name
- NCT00838838
- Testing
- Testosterone Undeconate (Nebido-R, BAY86-5037)
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Bayer
Hypogonadism, Male
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism.
- Trial name
- NCT06689085
- Testing
- Testosterone enanthate
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Halozyme Therapeutics
Hypogonadism
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
The purpose of this pharmacokinetic study is to determine whether oral testosterone (T) ester formulations can be used effectively to treat men with low testosterone.
- Trial name
- NCT00695110
- Testing
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clarus Therapeutics, Inc.
Prostate Cancer
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
The study drug, radium-223, gives off radiation that helps to kill cancer cells in the prostate. It is already available for patients to receive as a treatment for prostate cancer that has not responded to testosterone lowering…
- Trial name
- QOLRAD (NCT04681144)
- Testing
- Radium-223-dichloride (Xofigo, BAY88-8223)
- Where
- Colombia
- Volunteers
- 103 people
- Sponsor
- Bayer
Hypogonadism
Efficacy of an Intranasal Testosterone Product
This clinical trial will compare the pharmacokinetic profile of testosterone after repeated intranasal administration of TBS-1 of different strengths in subjects with hypogonadism
- Trial name
- NCT01252745
- Testing
- 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Hypogonadism
Evaluation of Testosterone Nasal Gel in Hypogonadal Boys
PK study to evaluate serum levels of testosterone post nasal delivery in two cohorts of hypogonadal boys.
- Trial name
- NCT03345797
- Testing
- Testosterone Nasal Gel [Natesto]
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- Acerus Biopharma Inc.
Hypogonadism
Oral Testosterone for the Treatment of Hypogonadism in Males
Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors.
- Trial name
- NCT02222558
- Testing
- TSX-002
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TesoRx Pharma, LLC
Hypogonadotropic Hypogonadism
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks.
- Trial name
- NCT02730169
- Testing
- BGS649
- Where
- 63 sites in United States, Italy and 2 more
- Volunteers
- 271 people
- Sponsor
- Mereo BioPharma
Biochemically Recurrent Prostate Cancer
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer. Hormone-naïve prostate cancer is a prostate cancer that has not yet been treated with hormonal therapy…
- Trial name
- ARAMON (NCT05526248)
- Testing
- Darolutamide(BAY1841788, Nubeqa), Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Bayer
Androgens (Deficiency), Male
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM. The effects on body composition (lean, fat and bone) and other symptoms of PADAM and safety will be…
- Trial name
- NCT00185198
- Testing
- Testogel (Testosterone, BAYV001915)
- Where
- 30 sites in Austria, Finland and 6 more
- Volunteers
- 363 people
- Sponsor
- Bayer